ChartRow logo
Data provided bySource: Twelve Data
JAZZ
$240.71+0.39%
as of close, Nov 17, 2026
☾ AH $240.71 +0.39%
Share this page

JAZZ — Jazz Pharmaceuticals plc Common Stock (Ireland) price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in JAZZ be worth today? →
JAZZ returns: By year · By month · By week · Trailing

Price data

Price
$240.71
YTD price return
+41.59%
YTD total return
+41.59%
Market cap
15.5B
Enterprise value
18.2B
Shares outstanding
64.2M
52W low
$156.95
52W high
$266.38
From 52W high
-9.64%
From 52W low
+53.37%
52W range
77%$157–$266
Beta
0.36

Volume

Rel volume
0.62×
30D volume
807K
30D $ vol
178.9M

Insider trading

Insider net 1W
none
Insider net 1M
−$18.1M
Insider net 3M
−$41.4M
Insider net 1Y
−$65.9M

Form 4 transactions by trade date, as filed; latest on file 2026-11-06.

Fundamentals

Sales (ttm)
4.7B
Sales/share
$73.50
EPS (ttm)
$3.15
FCF (ttm)
1.6B
FCF/share
$25.26
Book value/share
$65.30
Net margin
4.37%
ROE
4.91%
ROA
1.72%
Debt / equity
1.09×
Current ratio
1.82

Growth (CAGR, ttm) · 10Y

Sales
+13.49%+7.53%+10.51%+12.66%
Net income
n/a+37.07%n/a-5.51%
FCF
+21.35%+9.26%+16.21%+12.02%
Shares
+5.64%+0.65%+0.87%+0.70%

Per-share growth (CAGR, ttm) · 10Y

EPS
n/a+40.06%n/a-5.96%
Sales/share
+7.43%+6.84%+9.56%+11.89%
FCF/share
+14.87%+8.55%+15.21%+11.24%
Book value/share
+0.23%+5.62%+0.38%+8.59%
Price
+41.55%+25.91%+12.58%+7.99%
Total return
+41.55%+25.91%+12.58%+7.99%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
76.3×
P/OI (ttm)
36.3×
Fwd P/E
9.3×
P/S (ttm)
3.3×
P/B (mrq)
3.7×
P/FCF (ttm)
9.5×
EV/EBITDA (fy)
15.9×
EV/Sales (ttm)
3.9×
FCF yield (ttm)
10.50%
Buyback yield (realized, 1y)
-5.64%
Shareholder yield (realized, 1y)
-5.64%
Buyback yield (cash, ttm)
1.46%
Shareholder yield (cash, ttm)
1.46%

Vs own 10Y history

P/E
89th
P/OI
82nd
P/S
55th
P/B
90th
P/FCF
48th

Bar = where today’s multiple sits in JAZZ’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.39%
5D
-1.92%
1M
+14.50%
3M
-3.08%
YTD
+41.59%
1Y
+41.52%
5Y
+80.86%
1D
+0.39%
5D
-1.92%
1M
+14.50%
3M
-3.08%
YTD
+41.59%
1Y
+41.52%
5Y
+80.86%

Fundamentals#

Revenue

5Y CAGR +12.5%10Y CAGR +12.4%YoY +10.4%
$4.7B TTM$1.2B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
$426M TTM−$413.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y n/mYoY n/m
$3.15 TTM−$7.48 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +8.0%10Y CAGR +10.1%YoY +6.6%
$1.6B TTM$489.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.7B, capex −$70.8M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $506.1M, capex −$16.2M

Shares (diluted)

5Y +7.9%10Y −3.3%YoY +5.0%
65.3M TTM64.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
$206M TTM−$483.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full JAZZ financials →

About Jazz Pharmaceuticals#

Data provided bySource: Twelve Data

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.

Dublin, Ireland·2,890 employees·Biotechnology·jazzpharma.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding JAZZ#

20 of the 193 ETFs ChartRow carries live hold JAZZ. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IJHiShares Core S&P Mid-Cap ETF0.4%
MDYSPDR S&P MidCap 400 ETF Trust0.4%
VBRVanguard Small-Cap Value ETF0.3%
VHTVanguard Health Care ETF0.2%
VXFVanguard Extended Market ETF0.2%
VBVanguard Small-Cap ETF0.2%
IWSiShares Russell Mid-Cap Value ETF0.1%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%